Abstract LB-170: Breast cancer incidence and hormone therapy use before and after the Women’s Health Initiative (WHI) estrogen (E) plus progestin (P) trial by race/ethnicity

We examined breast cancer incidence in US women, 50 years or older, from the Surveillance, Epidemiology and End Results (SEER) program through 2015 in relation to estrogen (E) plus progestin (P) and E alone use before and after 2002, when adverse E plus P breast cancer effects in the WHI trial were initially reported. Age-adjusted annual breast cancer incidence rates for all US women averaged over the five-year intervals of 1983-1987, 1988-1992,...